Side-by-side · Research reference
TestagenvsTriptorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/41 cited
BFDA-ApprovedHUMAN-REVIEWED16/64 cited
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
Testagen
Triptorelin
Primary target
Testicular tissue; proposed nuclear DNA interaction
Pituitary GnRH receptorsUnknown 2012
Pathway
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
GnRH receptor agonism → initial flare (LH/FSH spike) → receptor desensitization → sustained LH/FSH suppression
Downstream effect
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Castration-level suppression of testosterone (men) and estrogen (women) within 2–4 weeks post-flare
Feedback intact?
Unknown — no HPG axis data
No — bypasses physiological pulsatility; continuous agonism produces paradoxical suppression
Origin
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Synthetic decapeptide analogue of native GnRH with amino acid substitutions for enhanced receptor affinity and stability
Antibody development
—
—
02Dosage Protocols
Parameter
Testagen
Triptorelin
Typical protocol (anecdotal)
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
—
Frequency
Once daily or alternate days
Every 1, 3, or 6 months per formulation
Cycle length
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
—
Evidence basis
Animal mechanistic / in vitro onlyFedoreyeva 2011
Multiple Phase 3 RCTs · FDA-approved 1999
Route
Subcutaneous
—
Reconstitution
Sterile water or bacteriostatic saline
—
Half-life
Unknown — likely minutes (short peptide)
—
1-month depot
—
3.75 mg IM
Most common formulation for prostate cancer.
6-month depot
—
Administration route
—
Intramuscular (IM) — gluteal or deltoid
Indication: Prostate cancer
—
Advanced (metastatic or locally advanced)
Androgen deprivation therapy (ADT) backbone.
Indication: Endometriosis
—
3.75 mg monthly
FDA-approved; typically 6-month course.
Indication: Central precocious puberty
—
Pediatric use (≥2 years)Jia 2025
Weight-based dosing per FDA label.
Duration (prostate cancer)
—
Continuous or intermittent ADT protocolsPreston 2024
Intermittent ADT may reduce side effects; cardiovascular risk similar to continuous.
Monitoring
—
Serum testosterone, PSA (prostate cancer), bone density, lipids, glucose
04Side Effects & Safety
Parameter
Testagen
Triptorelin
Injection site reactions
Erythema, mild irritation (potential)
Pain, erythema, sterile abscess (rare with depot formulations)
Systemic effects
Unknown — no human safety data
—
Hormonal impact
No published data on testosterone, LH, FSH effects
—
Long-term safety
Unknown — no long-term studies
—
Initial flare symptoms
—
Bone pain, urinary obstruction, spinal cord compression (first 2 weeks)
Antiandrogen co-treatment (bicalutamide) mitigates flare in metastatic disease.
Cardiovascular events
—
MI, stroke, arrhythmia — GnRH agonists show higher CV risk vs antagonists in meta-analysesPatel 2025Preston 2024
Hot flashes
—
Very common (>60%); vasomotor instability
Bone loss / Osteoporosis
—
Accelerated bone mineral density decline; fracture risk ↑Friedrich 2025
Baseline DEXA scan recommended; bisphosphonates or denosumab may be indicated.
Metabolic syndrome
—
Weight gain, insulin resistance, dyslipidemia, diabetes risk
Gynecomastia / Breast tenderness
—
Common (10–20%); peripheral aromatization of residual androgens
Fatigue / Mood changes
—
Anemia, depression, cognitive changes reported in long-term ADT
Hepatotoxicity
—
Transient transaminase elevations; clinically apparent liver injury rare
Racial differences (ADT)
—
Black veterans show higher CV event rates vs White veterans on GnRH agonists
Absolute Contraindications
Testagen
- ·Active testicular malignancy
Triptorelin
- ·Hypersensitivity to triptorelin, GnRH, or GnRH agonist analogues
- ·Pregnancy (Category X)
Relative Contraindications
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
Triptorelin
- ·Active cardiovascular disease — consider GnRH antagonist alternative
- ·Metastatic vertebral disease with spinal cord compression risk (flare hazard)
- ·Severe urinary obstruction — may worsen during flare
- ·Osteoporosis or high fracture risk (requires bone-protective therapy)
05Administration Protocol
Parameter
Testagen
Triptorelin
1. Reconstitution
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
Choose 1-month (3.75 mg), 3-month (11.25 mg), or 6-month (22.5 mg) depot based on adherence needs and clinical context. 6-month formulation shows improved real-world adherence in Asia-Pacific cohorts.
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
Intramuscular — gluteal or deltoid muscle. Use 21–23G needle. Aspirate to confirm non-vascular placement. Rotate sites with repeat injections.
3. Timing
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
For metastatic prostate cancer: co-administer antiandrogen (e.g., bicalutamide 50 mg daily) starting 1 week before first injection and continuing 2–4 weeks to prevent tumor flare.
4. Storage
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
Baseline: testosterone, PSA, bone density (DEXA), lipids, glucose. Follow-up: testosterone at 4 weeks (confirm <50 ng/dL castration), PSA monthly × 3, then quarterly. Annual DEXA for bone loss.
5. Cycle protocol
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.
Store vials at room temperature (20–25 °C), protect from light. Do not freeze. Reconstituted suspension should be used immediately.
6. Intermittent ADT protocol (optional)
—
Some protocols use on-treatment periods (9–12 months) alternating with off-treatment intervals until PSA rises. Cardiovascular risk appears similar to continuous ADT.